Saneron CCEL Therapeutics, a Cryo-Cell International affiliated company, along with a group of researchers and colleagues of the University of South Florida has participated in a new research study of human umbilical cord blood stem cell’s treatment of stroke. In collaboration with the Henry Ford Hospital’s Neurology Department, Saneron concluded that human umbilical cord blood stem cells have a positive neuro-restorative effect on the post-stroke brain in diabetic rats.
Stroke study in rats
In this study, type one diabetes mellitus rats were subjected to a stroke. The experimental group was then injected with human umbilical cord blood stem cells provided by Saneron CCEL Therapeutics within 24 hours of trauma. By targeting the mechanisms1 that affect the brain after a stroke with the cord blood stem cells, the researchers were able to induce brain remodeling, decrease harmful inflammation and promote vascular remodeling to supply the damaged brain with nutrients. The treated rats exhibited greatly improved brain function as seen in motor control tests and impressive brain recovery signaled by brain samples.
Current treatment risk in diabetics
The current gold standard for stroke treatment is the intra-venous injection of t-PA
to dissolve blood clots in the brain. The treatment is too risky for many diabetics and not used for hemorrhagic strokes due to the risk of deadly bleeding in the brain and poor recovery outcomes.
Promise in stem cells
This research will hopefully lead to new stroke treatments for humans with umbilical cord blood stem cells, especially among those suffering from diabetes. The world’s 382 million diabetics are 2.5 times more likely to develop cardiovascular diseases including stroke. The human umbilical cord blood stem cells ability to resupply the brain with blood without increasing risk of hemorrhage may help to curb the second most frequent cause of death and improve recovery worldwide.
HUCBCs Increase Angiopoietin 1 and Induce Neurorestorative Effects after Stroke in T1DM Rats
Stroke Risk and Diabetes
About Saneron CCEL Therapeutics, Inc.
Saneron CCEL Therapeutics, Inc. is a biotechnology R&D company, focused on neurological and cardiac cell therapy for the early intervention and treatment of several devastating or deadly diseases, which lack adequate treatment options. Saneron, a University of South Florida spin-out company is located at the Tampa Bay Technology Incubator. An affiliate of Cryo-Cell International, Inc., Saneron is committed to providing readily available, noncontroversial stem cells for cellular therapies and has patented and patent-pending technology relating to our platform technology of umbilical cord blood and Sertoli cells.
Researchers targeted two specific genes (Angiopoietin-1 and RAGE) effectively up regulating and suppressing their expression respectively. The RAGE signaling pathway has been implicated in promoting inflammation, neuronal death, vascular injury and brain damage following ischemia. Angiopoietin-1 is a protein with potent roles in vascular remodeling, protection and angiogenesis.